NantHealth CEO Patrick Soon-Shiong said that the company is seeking a fast-track FDA clearance predicated on Memorial Sloan Kettering's 468-gene panel.
Investigators from the pharma concluded that most liquid biopsy false positives and negatives could be traced to technical specifics of individual tests.
A survey of more than 2,400 pregnant women found that their views on testing largely fell into four clusters, shaped by their thoughts on risk, ambiguity, and more.
A genomic and transcriptomic analysis of an aggressive form of leukemia suggests that subtypes differ in their prognosis and may respond to different therapies.
The acquisition will result in a new DLS division called HudsonAlpha Discovery that will provide a range of services to the pharma, biotech, and diagnostics industries.
This week's news includes Thermo Fischer Scientific, NanoString Technologies, Caris Life Sciences, OpGen, Genfit, Oxford Immunotec, and American Esoteric Laboratories.
The deal will bring together the companies' respective multiplexed immunofluorescence immunohistochemistry and digital image analysis technologies.
The firm is partnering with the Cleveland Clinic to validate its mutation variant caller platform in hepatocellular cancer cell-free tumor DNA samples.
Seven Bridges has named promoted William Moss to CEO from his previous role as chief operations officer and president of commercial operations. He replaces Brandi Davis-Dusenbery, who has moved into the newly created position of chief scientific officer for the company. Davis-Dusenbery had been CEO since March 2017.
A report from Universities Allied for Essential Medicines and TranspariMed finds some US research institutions are slow to report their clinical trial findings, Nature News says.
A bi-weekly listing of recent local coverage determinations from Medicare Administrative Contractors.
Fluidigm launched Maxpar Direct Immune Profiling System; researchers can now quantify 37 different immune cell populations from human peripheral blood mononuclear cells & whole blood using a simple automated single-tube workflow in five minutes.
RareCyte is introducing its CyteFinder II and CyteFinder II HT instruments, next-generation versions of the company's CyteFinder instruments for multi-omic liquid biopsy and tissue research in clinical labs. Both instruments perform rapid, whole-slide imaging in seven fluorescence channels as well as brightfield for immunofluorescence, immunohistochemistry, and H&E.
CyteFinder II offers researchers a complete workflow in a single platform for imaging through cell retrieval of both liquid biopsy and tissue samples. The integrated CytePicker Retrieval Module enables discovery research by providing image-guided cell retrieval for high-depth sequencing. This workflow can be used for circulating tumor cell mutational analysis, RNA-based T-cell receptor discovery, and differential expression analysis of tissue microenvironments.
CyteFinder II HT meets the demand of high-volume pathology and liquid biopsy labs with hands-free, rapid, whole-slide scanning of up to 80 slides and a barcode-driven workflow for sample tracking. The machine learning-driven workflow for rare cell detection and automated tissue finding make CyteFinder II HT ideal for clinical researchers performing either cellular or tissue-based multiplexed analysis.
Fluidigm has launched the Maxpar Direct Immune Profiling System, which enables researchers to quantify 37 different immune cell populations from human peripheral blood mononuclear cells and whole blood using a simple automated single-tube workflow in five minutes. The new system provides a more comprehensive immune cell profile from both PBMC and whole blood and a user workflow that is significantly improved from the company's Maxpar Human Immune Monitoring Panel Kit. The system contains a 30-marker antibody panel that was developed with input from expert immunologists from academia and biopharma to identify and count 37 different immune cell subsets. Provided in a dry format in ready-to-use assay tubes, it enables researchers to easily stain samples and acquire results using the Fluidigm Helios mass cytometry system, the company said. Researchers can also add up to seven new antibodies to the panel to support specific study goals. Automated single-cell selection and results reporting is completed in just five minutes using the Maxpar Pathsetter software, developed with Verity Software House, Fluidigm said.
Quanterix said this week that it has appointed Amol Chaubal as CFO, effective April 12, 2019. He replaces Joseph Driscoll, who is stepping down as CFO. Chaubal joins Quanterix from medical device firm Smith & Nephew, where he currently serves as CFO of global operations. Prior to Smith & Nephew, he served as corporate VP and head of finance for Parexel's CRS business, and has also held various roles at Novartis, including CFO North America – Vaccines & Diagnostics.
Qiagen is launching its exoRNeasy Midi and Maxi Kits for isolation of exosomes and other extracellular vesicles from urine and other samples, as well as the miRNeasy 96 Advanced QiaCube HT Kit for automated purification of total RNA, including miRNA, from serum and plasma samples.
The exoRNeasy Midi and Maxi Kits use membrane affinity technology for RNA isolation from exosomes and other extracellular vesicles, and can provide results in about an hour, the company said. The Midi column enables processing of smaller sample volumes (1 ml serum/plasma and 4 ml or less of urine), while the Maxi format allows the use of large sample volumes (up to 4 ml serum/plasma, 16 ml of urine, and 32 ml of cell culture supernatant).
The miRNeasy 96 Advanced QiaCube HT Kit is designed for automated high-throughput purification of cell-free total RNA, primarily miRNA and other small RNA, from small volumes of serum and plasma on the QiaCube HT instrument. The phenol-free protocol uses easy-to-automate spin column technology in a 96-well format and minimizes hands-on time to remove contaminants and inhibitors, the company noted.
The company also said it is launching new bundles of its bioinformatics solutions with preconfigured QiaSeq DNA panels and custom panels for use on any sequencing platform, as well as with QiaAct targeted gene and custom panels for use on the Qiagen GeneReader NGS System. The new assay-and-software bundles include Qiagen's CLC Genomics Workbench and Clinical Insight-Interpret (QCI-I) for QiaSeq DNA panels and QCI-I for QiaAct panels.
The company is seeking NY State approval for its lab, which would allow it to offer both tests as LDTs, hopefully by the end of this year or early next.